RIGI and colorectal carcinoma: In terms of the specific mechanism, RIG-I inhibits the ubiquitination and proteasomal degradation of PD-L1 by competitively binding to PD-L1 with Speckle-type POZ proteins (SPOPs), thereby maintaining its stability and ultimately promoting immune escape in CRC (17).